A. Dopazo
AuthID: R-006-JP4
1
TITLE: TRIB2 confers resistance to anti-cancer therapy by activating the serine/threonine protein kinase AKT
AUTHORS: Richard Hill; Patricia A Madureira; Bibiana Ferreira; Ines Baptista; Susana Machado; Laura Colaco; Marta dos Santos; Ningshu S Liu; Ana Dopazo; Selma Ugurel; Angyal Adrienn; Endre Kiss Toth; Murat Isbilen; Ali O Gure; Wolfgang Link;
PUBLISHED: 2017, SOURCE: NATURE COMMUNICATIONS, VOLUME: 8
AUTHORS: Richard Hill; Patricia A Madureira; Bibiana Ferreira; Ines Baptista; Susana Machado; Laura Colaco; Marta dos Santos; Ningshu S Liu; Ana Dopazo; Selma Ugurel; Angyal Adrienn; Endre Kiss Toth; Murat Isbilen; Ali O Gure; Wolfgang Link;
PUBLISHED: 2017, SOURCE: NATURE COMMUNICATIONS, VOLUME: 8
INDEXED IN: 
Scopus 
WOS
Scopus WOS2
TITLE: A novel phosphatidylinositol 3-kinase (PI3K) inhibitor directs a potent FOXO-dependent, p53-independent cell cycle arrest phenotype characterized by the differential induction of a subset of FOXO-regulated genes
AUTHORS: Richard Hill; Ravi Kiran Reddy Kalathur; Sergio Callejas; Laura Colaco; Ricardo Brandao; Beatriz Serelde; Antonio Cebria; Carmen Blanco Aparicio; Joaquin Pastor; Matthias Futschik ; Ana Dopazo; Wolfgang Link;
PUBLISHED: 2014, SOURCE: BREAST CANCER RESEARCH, VOLUME: 16, ISSUE: 6
AUTHORS: Richard Hill; Ravi Kiran Reddy Kalathur; Sergio Callejas; Laura Colaco; Ricardo Brandao; Beatriz Serelde; Antonio Cebria; Carmen Blanco Aparicio; Joaquin Pastor; Matthias Futschik ; Ana Dopazo; Wolfgang Link;
PUBLISHED: 2014, SOURCE: BREAST CANCER RESEARCH, VOLUME: 16, ISSUE: 6
3
TITLE: Identification of Disease-Relevant Genes for Molecularly-Targeted Drug Discovery
AUTHORS: Kauselmann, G; Dopazo, A; Link, W;
PUBLISHED: 2012, SOURCE: CURRENT CANCER DRUG TARGETS, VOLUME: 12, ISSUE: 1
AUTHORS: Kauselmann, G; Dopazo, A; Link, W;
PUBLISHED: 2012, SOURCE: CURRENT CANCER DRUG TARGETS, VOLUME: 12, ISSUE: 1
